# Etoricoxib vs. Diclofenac in OA (0663-805)(COMPLETED)

> **NCT00542087** · PHASE3 · COMPLETED · sponsor: **Organon and Co** · enrollment: 516 (actual)

## Conditions studied

- Osteoarthritis

## Interventions

- **DRUG:** MK0663, etoricoxib / Duration of Treatment: 6 Weeks
- **DRUG:** Comparator: diclofenac sodium / Duration of Treatment: 6 Weeks

## Key facts

- **NCT ID:** NCT00542087
- **Lead sponsor:** Organon and Co
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-03-22
- **Primary completion:** 2002-12-20
- **Final completion:** 2002-12-20
- **Target enrollment:** 516 (ACTUAL)
- **Last updated:** 2024-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00542087

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00542087, "Etoricoxib vs. Diclofenac in OA (0663-805)(COMPLETED)". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00542087. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*